ArticleCureus2026
Comparison of Short-Term Outcomes of Tetralogy of Fallot Repair Between Preserved Pulmonary Valve Annulus and Transannular Patch.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTetralogy of Fallot (TOF) repair may involve either preservation of the pulmonary valve annulus (PVA) or use of a transannular patch (TAP) with a polytetrafluoroethylene (PTFE) bicuspid pulmonary valve. This study aimed to compare short-term clinical and echocardiographic outcomes of TOF repair using preserved PVA versus TAP with PTFE valve.
methodsThis prospective, comparative, cross-sectional study was conducted from January 2022 to December 2023 at the National Heart Foundation Hospital & Research Institute, Dhaka. A total of 46 TOF patients were enrolled: 23 underwent PVA-preserving repair (Group A) and 23 received TAP with PTFE bicuspid valve (Group B). Data on postoperative ventilation time, vasoactive inotrope score (VIS), intensive care unit (ICU) stay, morbidity, and echocardiographic parameters were collected up to 12 weeks post discharge. Statistical analysis was performed using Mann-Whitney U and Fisher's exact tests.
resultsGroup A demonstrated significantly shorter ventilation time (median 5.0 vs. 19.0 hours, p = 0.001), lower VIS (median 9.0 vs. 13.5, p = 0.002), and reduced ICU stay (median 6.0 vs. 7.0 days, p = 0.023). The tricuspid regurgitation peak pressure gradient was significantly lower in Group A at all follow-up points (p < 0.05). No significant differences were observed in overall morbidity, mortality, or incidence of pulmonary regurgitation and right ventricular dysfunction between groups, and no patient required immediate redo surgery for residual right ventricular outflow tract obstruction.
conclusionPVA-preserving TOF repair is associated with better early recovery metrics. However, TAP with a PTFE bicuspid valve remains a safe and effective alternative when valve preservation is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.